Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure
Completed
- Conditions
- Blood Pressure
- Registration Number
- NCT00925470
- Lead Sponsor
- AstraZeneca
- Brief Summary
Evaluation of target organs impairment on patients suffering from high blood pressure without known cardio vascular or renal disease, stratified on blood pressure control.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1200
Inclusion Criteria
- Adults with hypertension (treated or not), without known cardiovascular or renal disease.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the frequency of evaluation of target organs preclinical impairment on patients without known cardiovascular or renal disease, taking into consideration the blood pressure level (controlled HBP or not) Once
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie target organ damage in hypertension patients without cardiovascular or renal disease as studied in NCT00925470?
How does blood pressure control impact organ-specific outcomes in NCT00925470 compared to standard-of-care antihypertensive regimens?
What biomarkers are associated with early target organ impairment detection in NCT00925470's observational cohort?
Are there novel therapeutic strategies for preventing organ damage in hypertension patients identified through NCT00925470's findings?
How do AstraZeneca's observational studies on hypertension (NCT00925470) contribute to understanding renal and cardiovascular risk stratification?
Trial Locations
- Locations (1)
Research Site
🇫🇷Yvetot, France
Research Site🇫🇷Yvetot, France